£86 million has been allocated by the Department for Business, Energy and Industrial Strategy and the Department of Health and Social Care as follows:<\/p>
<\/p>
- £39 million to improve local adoption and uptake of innovative medical technologies through the 15 Academic Health Science Networks, who will be given increased capacity to help innovative products find the right support and to promote regional adoption and spread;<\/p>
- £35 million over four years to encourage and support innovators to develop more world-leading digital solutions. Through the Digital Health Technology Catalyst, small and medium-sized enterprises (SME)-led projects will be supported to develop the evidence base required to launch their products in the National Health Service;<\/p>
- £6 million to help the NHS to adopt and integrate new technologies into everyday practice, through the Pathway Transformation Fund; and<\/p>
- £6 million over three years from the Industrial Strategy Challenge Fund to support SMEs to address the difficulties they face in getting their new medicines and medical technologies adopted in the market by supporting them to gather the evidence required to prove clinical efficacy.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "answeringMemberConstituency" : {"_value" : "Gosport"} , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"} , "dateOfAnswer" : {"_value" : "2018-04-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-04-18T09:57:59.1Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-04-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how the £86 million to support innovators and the NHS in overcoming barriers to getting new, innovative technologies to patients as part of the Accelerated Access Review will be allocated.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"} } , "tablingMemberConstituency" : {"_value" : "Leeds North West"} , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"} ], "uin" : "135438"} , {"_about" : "http://data.parliament.uk/resources/850719", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/850719/answer", "answerText" : {"_value" : "
As set out in the response to the Accelerated Access Review, the Accelerated Access Pathway was established with the purpose of getting those innovations that we believe will be truly transformative to patients more quickly. The pathway will open in April for product selection. Exact timing of when the first products will reach the National Health Service will depend on those products selected. The Pathway will be open to medicines, devices, diagnostics and digital products.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-03-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-03-05T15:57:36.33Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-02-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when the first treatments and technologies chosen for the Accelerated Access Pathway will be available for the NHS to use.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"} } , "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"} , "tablingMemberPrinted" : [{"_value" : "Dame Cheryl Gillan"} ], "uin" : "129961"} , {"_about" : "http://data.parliament.uk/resources/833871", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/833871/answer", "answerText" : {"_value" : "
As set out in the response to the Accelerated Access Response published in November 2017, the pathway will be developed and owned by the newly created Accelerated Access Collaborative (AAC), a partnership between the National Health Service, industry, and clinical and patient representatives. The AAC met for the first time on 31 January and it will be that group\u2019s responsibility to determine the criteria for the pathway. We anticipate that the AAC will publish further details on the process and criteria for the pathway ahead of the pathway opening in April 2018.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-02-07", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-02-07T14:05:49.767Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-01-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when he plans to publish the criteria to access the accelerated access pathway.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"} } , "tablingMemberConstituency" : {"_value" : "North Tyneside"} , "tablingMemberPrinted" : [{"_value" : "Mary Glindon"} ], "uin" : "125629"} , {"_about" : "http://data.parliament.uk/resources/818651", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/818651/answer", "answerText" : {"_value" : "
We are introducing a new Accelerated Access Pathway, to streamline regulatory and market access decisions, getting breakthrough products that we believe will be truly transformative to patients more quickly. A new Accelerated Access Collaborative (AAC) chaired by Sir Andrew Witty, will develop and own the Accelerated Access Pathway which will be operational from April 2018. All products including medical technologies, devices and diagnostics will be eligible for selection. In addition to the new Pathway, the AAC will also make recommendations to the Government and its partners about opportunities to further streamline existing routes to market.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-01-16", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-01-16T12:04:46.697Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2018-01-08", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, with reference to the Government response to the Accelerated Access Review published in November 2017, what plans his Department has to streamline existing routes to market for medical technologies, devices and diagnostics.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4412", "label" : {"_value" : "Biography information for Dr Lisa Cameron"} } , "tablingMemberConstituency" : {"_value" : "East Kilbride, Strathaven and Lesmahagow"} , "tablingMemberPrinted" : [{"_value" : "Dr Lisa Cameron"} ], "uin" : "121415"} , {"_about" : "http://data.parliament.uk/resources/806540", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/806540/answer", "answerText" : {"_value" : "
The Government and partners published the response to the Accelerated Access Review on 3 November which outlines plans for implementation. Since the Accelerated Access Collaborative has not yet selected any products, we have not made any assessment of the effect of implementation on any particular condition. The Accelerated Access Pathway will be operational from April 2018 when it will begin selecting products.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-12-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-12-21T16:49:37.937Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-12-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the effect of implementation of the recommendations of the Accelerated Access review on services to people with (a) Cystic Fibrosis and (b) other long-term conditions; and will he make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"} } , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"} , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"} ], "uin" : "119616"} , {"_about" : "http://data.parliament.uk/resources/806545", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/806545/answer", "answerText" : {"_value" : "
The Government and partners published the response to the Accelerated Access Review on 3 November which outlines plans for implementation. Since the Accelerated Access Collaborative has not yet selected any products, we have not made any assessment of the benefits for any particular condition. The Accelerated Access Pathway will be operational from April 2018 when it will begin selecting products.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-12-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-12-21T16:48:34.653Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-12-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment his Department has made of the potential benefits for people with long-term conditions such as cystic fibrosis of implementing the recommendations of the accelerated access review; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1528", "label" : {"_value" : "Biography information for Sir Mike Penning"} } , "tablingMemberConstituency" : {"_value" : "Hemel Hempstead"} , "tablingMemberPrinted" : [{"_value" : "Sir Mike Penning"} ], "uin" : "119621"} , {"_about" : "http://data.parliament.uk/resources/784929", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/784929/answer", "answerText" : {"_value" : "
As set out in the response to the Accelerated Access Review, published on 3 November, we anticipate that around five breakthrough products will be selected each year. The Accelerated Access Pathway will be open to products from April 2018.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-11-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-11-13T16:59:28.55Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-11-06", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the number of products that will be considered for breakthrough status through the Accelerated Access Pathway in the next financial year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "111599"} , {"_about" : "http://data.parliament.uk/resources/784930", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/784930/answer", "answerText" : {"_value" : "
Ministers and officials from the Department meet regularly with the pharmaceutical industry to discuss policy development and implementation. Engagement will continue on the implementation of the Accelerated Access pathway and criteria for breakthrough products.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-11-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-11-13T17:26:42.517Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-11-06", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what discussions he has had with the pharmaceutical industry on the cost effectiveness criteria for new treatments seeking breakthrough designation through the Accelerated Access Pathway.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "111600"} , {"_about" : "http://data.parliament.uk/resources/784940", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/784940/answer", "answerText" : {"_value" : "
The Accelerated Access Collaborative (AAC) will define the criteria for breakthrough products in the coming months. As set out in the response to the Accelerated Access Response, the AAC will focus on affordable products which can dramatically improve efficiency, fill an unmet need or make a step change in patient outcomes.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-11-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-11-13T16:56:25.57Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-11-06", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the capacity of the Accelerated Access Pathway to consider treatments for rare diseases, including muscle-wasting conditions, to be considered for fast-track breakthrough designation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "111598"} , {"_about" : "http://data.parliament.uk/resources/771344", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/771344/answer", "answerText" : {"_value" : "
The Government and its partners are carefully considering the recommendations in the Accelerated Access Review. A response will be published shortly, where we will outline plans for improving patient access to transformative treatments at a price the National Health Service can afford.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-10-24", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-10-24T14:29:57.957Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-10-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Innovative Medicines and Medical Technology Review"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, when he plans to implement the recommendations of the Accelerated Access Review, published on 24 October 2016.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4082", "label" : {"_value" : "Biography information for Lisa Nandy"} } , "tablingMemberConstituency" : {"_value" : "Wigan"} , "tablingMemberPrinted" : [{"_value" : "Lisa Nandy"} ], "uin" : "107744"} ], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-ddpModified.=2017-07-10T17%3A03%3A11.017Z&hansardHeading=Innovative+Medicines+and+Medical+Technology+Review", "page" : 0, "startIndex" : 1, "totalResults" : 12, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }